## Hans-Peter Schmid

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1385802/publications.pdf

Version: 2024-02-01

279798 144013 3,556 109 23 57 citations h-index g-index papers 114 114 114 3447 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	In-hospital cost analysis of aquablation compared with transurethral resection of the prostate in the treatment of benign prostatic enlargement. Swiss Medical Weekly, 2022, 152, w30136.	1.6	1
2	Prostatic Artery Embolisation: Do We Still Need It and for Whom?. European Urology Focus, 2022, 8, 384-387.	3.1	4
3	Informative value of histological assessment of tissue acquired during aquablation of the prostate. World Journal of Urology, 2021, 39, 2043-2047.	2.2	7
4	Adherence to European Association of Urology and National Comprehensive Cancer Network Guidelines Criteria for Inguinal and Pelvic Lymph Node Dissection in Penile Cancer Patients—A Survey Assessment in German-speaking Countries on Behalf of the European Prospective Penile Cancer Study Group. European Urology Focus, 2021, 7, 843-849.	3.1	12
5	Systematic assessment of information about surgical urinary stone treatment on YouTube. World Journal of Urology, 2021, 39, 935-942.	2.2	16
6	Reduction of stentâ€essociated morbidity by minimizing stent material: a prospective, randomized, singleâ€blind superiority trial assessing a customized †suture stent'. BJU International, 2021, 127, 596-605.	2.5	16
7	Stay cool! Special underwear for cyclic cooling significantly decreases scrotal skin temperature. Central European Journal of Urology, 2021, 74, 468-470.	0.3	1
8	Reasons to consider prostatic artery embolization. World Journal of Urology, 2021, 39, 2301-2306.	2.2	9
9	Identifying classes of the pain, fatigue, and depression symptom cluster in long-term prostate cancer survivors—results from the multi-regional Prostate Cancer Survivorship Study in Switzerland (PROCAS). Supportive Care in Cancer, 2021, 29, 6259-6269.	2.2	9
10	Radiation Exposure During Prostatic Artery Embolisation: A Systematic Review and Calculation of Associated Risks. European Urology Focus, 2021, 7, 608-611.	3.1	19
11	Aquablation versus holmium laser enucleation of the prostate in the treatment of benign prostatic hyperplasia in medium-to-large-sized prostates (ATHLETE): protocol of a prospective randomised trial. BMJ Open, 2021, 11, e046973.	1.9	3
12	Prostatic Artery Embolisation Versus Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia: 2-yr Outcomes of a Randomised, Open-label, Single-centre Trial. European Urology, 2021, 80, 34-42.	1.9	64
13	Safety of Magnetic Resonance Imaging in patients under Sacral Neuromodulation with an InterStim Neuromodulator. Urology, 2021, 154, 115-119.	1.0	1
14	Radiotherapy or Surgery? Comparative, Qualitative Assessment of Online Patient Education Materials on Prostate Cancer. Current Oncology, 2021, 28, 3420-3429.	2.2	9
15	Qualitative Assessment of Medical Information on YouTube: A Multilingual Comparison of Common Urological Conditions. Urologia Internationalis, 2021, 105, 757-763.	1.3	5
16	Does the Identification of a Minimum Number of Cases Correlate With Better Adherence to International Guidelines Regarding the Treatment of Penile Cancer? Survey Results of the European PROspective Penile Cancer Study (E-PROPS). Frontiers in Oncology, 2021, 11, 759362.	2.8	7
17	Re: Early Results of Unilateral Prostatic Artery Embolization as a Focal Therapy in Patients with Prostate Cancer Under Active Surveillance: Cancer Prostate Embolisation, a Pilot Study. European Urology, 2021, 81, 121-121.	1.9	O
18	Information on surgical treatment of benign prostatic hyperplasia on YouTube is highly biased and misleading. BJU International, 2020, 125, 595-601.	2.5	44

#	Article	IF	Citations
19	Ejaculatory disorders after prostatic artery embolization: a reassessment of two prospective clinical trials. World Journal of Urology, 2020, 38, 2595-2599.	2.2	18
20	First Report of a Symptomatic Calculus of the Ampulla of the Ductus Deferens. Journal of Endourology Case Reports, 2020, 6, 253-255.	0.3	1
21	Healthâ€related quality of life in longâ€term prostate cancer survivors after nerveâ€sparing and nonâ€nerveâ€sparing radical prostatectomy—Results from the multiregional PROCAS study. Cancer Medicine, 2020, 9, 5416-5424.	2.8	6
22	Initial Diagnosis and Detection of Very Late Local Recurrence of a Ductal Prostate Cancer due to a Ureteral Stone. Case Reports in Urology, 2020, 2020, 1-4.	0.3	0
23	Longâ€term oncological and functional followâ€up in lowâ€doseâ€rate brachytherapy for prostate cancer: results from the prospective nationwide Swiss registry. BJU International, 2020, 125, 827-835.	2.5	7
24	Urinary Stone Location with Ureteral Stents in Place: Always on the Move, and not Where you Would Expect. Urology Journal, 2020, 17, 667-670.	0.4	0
25	Symptoms Associated With Long-term Double-J Ureteral Stenting and Influence of Biofilms. Urology, 2019, 134, 72-78.	1.0	12
26	Spoilt for Choice: A Survey of Current Practices of Surgical Urinary Stone Treatment and Adherence to Evidence-Based Guidelines among Swiss Urologists. Urologia Internationalis, 2019, 103, 357-363.	1.3	6
27	Predictability and Inducibility of Detachment of Prostatic Central Gland Tissue after Prostatic Artery Embolization: Post Hoc Analysis of a Randomized Controlled Trial. Journal of Vascular and Interventional Radiology, 2019, 30, 217-224.	0.5	10
28	Detection of microbial colonization of the urinary tract of patients prior to secondary ureterorenoscopy is highly variable between different types of assessment: results of a prospective observational study. Biofouling, 2019, 35, 1083-1092.	2.2	3
29	Readability Assessment of Commonly Used German Urological Questionnaires. Current Urology, 2019, 13, 87-93.	0.6	0
30	Improving Patient Education Materials: A Practical Algorithm from Development to Validation. Current Urology, 2019, 13, 64-69.	0.6	11
31	Inâ€hospital cost analysis of prostatic artery embolization compared with transurethral resection of the prostate: <i>post hoc</i> analysis of a randomized controlled trial. BJU International, 2019, 123, 1055-1060.	2.5	21
32	Prostatic Artery Embolization versus Standard Surgical Treatment for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis. European Urology Focus, 2019, 5, 1091-1100.	3.1	80
33	Influence of biofilms on morbidity associated with short-term indwelling ureteral stents: a prospective observational study. World Journal of Urology, 2019, 37, 1703-1711.	2.2	9
34	Outcome prediction of prostatic artery embolization: <i>post hoc</i> analysis of a randomized, openâ€label, nonâ€inferiority trial. BJU International, 2019, 124, 134-144.	2.5	45
35	Readability Assessment of Patient Education Material Published by German-Speaking Associations of Urology. Urologia Internationalis, 2018, 100, 79-84.	1.3	11
36	Prostatic Artery Embolization in the Treatment of Localized Prostate Cancer: A Bicentric Prospective Proof-of-Concept Study of 12ÂPatients. Journal of Vascular and Interventional Radiology, 2018, 29, 589-597.	0.5	36

#	Article	IF	CITATIONS
37	Testicular sarcoidosis. Urology Case Reports, 2018, 17, 109-110.	0.3	12
38	CT-calculometry (CT-CM): advanced NCCT post-processing to investigate urinary calculi. World Journal of Urology, 2018, 36, 117-123.	2.2	7
39	Late seed migration after prostate brachytherapy with lod-125 permanent implants. Prostate International, 2018, 6, 66-70.	2.3	10
40	Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus ( <scp>HIV</scp> )â€protease inhibitors lopinavir or nelfinavir. BJU International, 2018, 121, 600-609.	2.5	11
41	Readability assessment of commonly used urological questionnaires. Investigative and Clinical Urology, 2018, 59, 297.	2.0	10
42	Comparison of prostatic artery embolisation (PAE) versus transurethral resection of the prostate (TURP) for benign prostatic hyperplasia: randomised, open label, non-inferiority trial. BMJ: British Medical Journal, 2018, 361, k2338.	2.3	210
43	Prediction of Bacteriuria Based on Clinical or Laboratory Parameters in Patients with Indwelling Ureteral Stents Before Ureterorenoscopy Should Not Substitute for Urine Cultures. Journal of Endourology, 2018, 32, 739-745.	2.1	4
44	The German linguistic validation of the Ureteral Stent Symptoms Questionnaire (USSQ). World Journal of Urology, 2017, 35, 443-447.	2.2	12
45	Absorption of Irrigation Fluid During Thulium Laser Vaporization of the Prostate. Journal of Endourology, 2017, 31, 380-383.	2.1	6
46	Re: Clinicopathological Features and Prognostic Value of Incidental Prostatic Adenocarcinoma in Radical Cystoprostatectomy Specimens: A Systematic Review and Meta-analysis of 13 140 Patients. European Urology, 2017, 72, 154-155.	1.9	1
47	Prevention and treatment of symptoms associated with indwelling ureteral stents: A systematic review. International Journal of Urology, 2017, 24, 250-259.	1.0	52
48	Readability assessment of online patient education materials provided by the European Association of Urology. International Urology and Nephrology, 2017, 49, 2111-2117.	1.4	23
49	Recurrent Dystrophic Calcification of the Prostatic Resection Cavity After Transurethral Resection of the Prostate: Clinical Presentation and Endoscopic Management. Journal of Endourology Case Reports, 2017, 3, 81-83.	0.3	6
50	Economic Aspects of Morbidity Caused by Ureteral Stents. Urologia Internationalis, 2016, 97, 91-97.	1.3	37
51	Life-Threatening Bleeding from Peristomal Varices after Cystoprostatectomy: Multimodal Approach in a Cirrhotic, Encephalopathic Patient with Severe Portal Hypertension. Case Reports in Urology, 2015, 2015, 1-3.	0.3	3
52	PSA bounce after 125I-brachytherapy for prostate cancer as a favorable prognosticator. Strahlentherapie Und Onkologie, 2015, 191, 787-791.	2.0	9
53	Influence of patient education on morbidity caused by ureteral stents. International Journal of Urology, 2015, 22, 679-683.	1.0	24
54	First Report on Joint Use of a Da Vinci® Surgical System with Transfer of Surgical Know-How between Two Public Hospitals. Urologia Internationalis, 2014, 93, 1-9.	1.3	0

#	Article	IF	CITATIONS
55	Information needs of early-stage prostate cancer patients: within- and between-group agreement of patients and health professionals. Supportive Care in Cancer, 2014, 22, 999-1007.	2.2	15
56	Ectopic Adrenocortical Tissue in the Spermatic Cord in a 44-Year-old Man. Urology Case Reports, 2014, 2, 169-170.	0.3	3
57	Prevention and early detection of prostate cancer. Lancet Oncology, The, 2014, 15, e484-e492.	10.7	372
58	Re: Refractory Chronic Pelvic Pain Syndrome in Men: Can Transcutaneous Electrical Nerve Stimulation Help?. European Urology, 2014, 65, 669-670.	1.9	0
59	Multidisciplinary care in patients with prostate cancer: room for improvement. Supportive Care in Cancer, 2013, 21, 2327-2333.	2.2	13
60	Therapeutic options for intractable hematuria in advanced bladder cancer. International Journal of Urology, 2013, 20, 651-660.	1.0	50
61	Bipolar versus Monopolar Transurethral Resection of the Prostate: Results of a Comparative, Prospective Bicenter Study – Perioperative Outcome and Long-Term Efficacy. Urologia Internationalis, 2013, 90, 62-67.	1.3	22
62	Ciprofloxacin and Epirubicin Synergistically Induce Apoptosis in Human Urothelial Cancer Cell Lines. Urologia Internationalis, 2012, 88, 343-349.	1.3	10
63	Extension of the therapeutic spectrum in castration-resistant prostate cancer: Osteoclast inhibition with denosumab. Translational Andrology and Urology, 2012, 1, 118-9.	1.4	3
64	High incidence of independent second malignancies after non-muscle-invasive bladder cancer. Scandinavian Journal of Urology and Nephrology, 2011, 45, 245-250.	1.4	8
65	Hereditary persistence of alpha-fetoprotein mimicking testicular cancer in a patient with acute epididymitis. Scandinavian Journal of Urology and Nephrology, 2011, 45, 354-355.	1.4	0
66	Nutrition, dietary supplements and adenocarcinoma of the prostate. Maturitas, 2011, 70, 339-342.	2.4	14
67	Consecutive Spontaneous Rupture of the Lower Pole Renal Artery and Main Renal Artery Due to Type 1 Neurofibromatosis. Urology, 2011, 77, 1339-1340.	1.0	3
68	Proposal for a standardized PSA doubling-time calculation. Anticancer Research, 2010, 30, 1633-6.	1.1	7
69	Prostatic Metastasis of Renal Cell Carcinoma Successfully Treated with Sunitinib. Urologia Internationalis, 2009, 83, 122-124.	1.3	9
70	The European Association of Urology (EAU) Guidelines Methodology: A Critical Evaluation. European Urology, 2009, 56, 859-864.	1.9	12
71	Re: Selective Inhibition of CYP17 with Abiraterone Acetate is Highly Active in the Treatment of Castration-Resistant Prostate Cancer. European Urology, 2009, 56, 744-745.	1.9	1
72	Exposure of Treating Physician to Radiation during Prostate Brachytherapy Using Iodine-125 Seeds. Strahlentherapie Und Onkologie, 2009, 185, 689-695.	2.0	10

#	Article	IF	CITATIONS
73	Health-Related Quality of Life after Radical Prostatectomy and Low-Dose-Rate Brachytherapy for Localized Prostate Cancer. Urologia Internationalis, 2009, 82, 17-23.	1.3	18
74	Feasibility of early intravesical instillation chemotherapy after transurethral resection of the bladder: A prospective evaluation in a consecutive series of 210 cases. Scandinavian Journal of Urology and Nephrology, 2008, 42, 522-527.	1.4	9
75	Prostate biopsy in Switzerland: A representative survey on how Swiss urologists do it. Scandinavian Journal of Urology and Nephrology, 2008, 42, 18-23.	1.4	8
76	Growth Hormone Inhibitors in Prostate Cancer: A Systematic Analysis. Urologia Internationalis, 2008, 81, 17-22.	1.3	7
77	Submucosal endocervicosis of the bladder: An ectopic, glandular structure of Mýllerian origin. Scandinavian Journal of Urology and Nephrology, 2008, 42, 88-90.	1.4	11
78	Rising Prostate-Specific Antigen after Primary Treatment of Prostate Cancer: Sequential Hormone Manipulation. Urologia Internationalis, 2007, 79, 95-104.	1.3	5
79	Prostate Biopsy in Central Europe: Results of a Survey of Indication, Patient Preparation and Biopsy Technique. Urologia Internationalis, 2007, 79, 60-66.	1.3	22
80	Re: Vaccination of Hormone-Refractory Prostate Cancer Patients with Peptide Cocktail-Loaded Dendritic Cells: Results of a Phase 1 Clinical Trial. European Urology, 2007, 51, 853-854.	1.9	0
81	Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma. Cancer Immunology, Immunotherapy, 2006, 55, 1524-1533.	4.2	104
82	Spontaneous Priapism after Radical Retropubic Prostatectomy. Urologia Internationalis, 2006, 77, 182-183.	1.3	1
83	Intermittent Ureteral Herniation – Rare Cause of Flank Pain. Urologia Internationalis, 2006, 77, 286-288.	1.3	1
84	Dendritic cells generated from patients with androgen-independent prostate cancer are not impaired in migration and T-cell stimulation. Prostate, 2005, 64, 323-331.	2.3	9
85	Biological Variation of Total Prostate-Specific Antigen: A Survey of Published Estimates and Consequences for Clinical Practice. Clinical Chemistry, 2005, 51, 1342-1351.	3.2	131
86	Update on screening for prostate cancer with prostate-specific antigen. Critical Reviews in Oncology/Hematology, 2004, 50, 71-78.	4.4	52
87	Prostate Specific Antigen Doubling Time as Auxiliary End Point in Hormone Refractory Prostatic Carcinoma. European Urology, 2003, 43, 28-30.	1.9	21
88	Semi-Quantitative Immunochromatographic Test for Prostate Specific Antigen in Whole Blood: Tossing the Coin to Predict Prostate Cancer?. European Urology, 2003, 43, 478-484.	1.9	31
89	Bicycle riding has no important impact on total and free prostate-specific antigen serum levels in older men. Urology, 2003, 61, 1177-1180.	1.0	25
90	Diagnosis of Prostate Cancer—The Clinical Use of Prostate Specific Antigen. EAU Update Series, 2003, 1, 3-8.	0.5	9

#	Article	IF	Citations
91	Accurate Control of the Superficial and Deep Dorsal Veins during Radical Retropubic Prostatectomy: The $M\tilde{A}\frac{1}{4}$ nster Clamp Technique. Urologia Internationalis, 2003, 70, 151-153.	1.3	2
92	Late Recurrence of Adenoid Cystic Carcinoma of the Prostate. Scandinavian Journal of Urology and Nephrology, 2002, 36, 158-159.	1.4	18
93	Combining Free and Total Prostate Specific Antigen Assays from Different Manufacturers: The Pitfalls. European Urology, 2002, 42, 577-582.	1.9	12
94	The rise and fall of PSA: clinical implications of prostate specific antigen kinetics. Urological Research, 2002, 30, 85-88.	1.5	16
95	Active Monitoring (Deferred Treatment or Watchful Waiting) in the Treatment of Prostate Cancer. European Urology, 2001, 40, 488-494.	1.9	19
96	Predictive Value of Radiological Criteria for Disintegration Rates of Extracorporeal Shock Wave Lithotripsy. Urologia Internationalis, 2001, 66, 127-130.	1.3	10
97	Five meters of H2O: The pressure at the urinary bladder neck during human ejaculation. Prostate, 2000, 44, 339-341.	2.3	40
98	Prostate-Specific Antigen Doubling Time: A Potential Surrogate End Point in Hormone-Refractory Prostate Cancer. Journal of Clinical Oncology, 1999, 17, 1644c-1644c.	1.6	5
99	Operative Therapy in Disease Progression and Local Recurrence of Renal Cell Carcinoma. Urologia Internationalis, 1999, 63, 10-15.	1.3	5
100	Hormonal Therapy of Prostate Cancer: Is There Any News?. Urologia Internationalis, 1999, 63, 80-85.	1.3	3
101	Impact of Minimal Lymph Node Metastasis on Long-Term Prognosis after Radical Prostatectomy. European Urology, 1997, 31, 11-16.	1.9	22
102	Longitudinal Evaluation of Prostate-Specific Antigen Levels in a Case-Control Study. European Urology, 1997, 31, 127-127.	1.9	12
103	In vivo and in vitro complex formation of prostate specific antigen with αi-anti-chymotrypsin. Prostate, 1995, 27, 166-175.	2.3	32
104	Serum free prostate specific antigen: Isoenzymes in benign hyperplasia and cancer of the prostate. Prostate, 1995, 27, 212-219.	2.3	65
105	Youssef's Syndrome: Preservation of Uterine Function with Subsequent Successful Pregnancy following Surgical Repair. Urologia Internationalis, 1994, 52, 220-222.	1.3	396
106	Clinical and Pathological Features of Highly Malignant Prostatic Carcinomas with Metastases to the Penis. Urologia Internationalis, 1994, 53, 135-138.	1.3	10
107	Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer, 1993, 71, 2031-2040.	4.1	356
108	Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer, 1993, 71, 933-938.	4.1	478

#	Article	IF	CITATIONS
109	An Abbreviated Standard Procedure for Accurate Tumor Volume Estimation in Prostate Cancer. American Journal of Surgical Pathology, 1992, 16, 184-191.	3.7	96